Trial Profile

A Phase I Study of Pevonedistat in Combination with Capecitabine-Oxaliplatin (CapeOX) in Patients with Platinum-Refractory Advanced Gastric Cancer

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 13 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Capecitabine (Primary) ; Oxaliplatin (Primary) ; Pevonedistat (Primary)
Indications Adenocarcinoma; Gastric cancer
Focus Adverse reactions; Pharmacokinetics

Most Recent Events

14 Dec 2023 New trial record
24 Oct 2023 Results assessing the safety and efficacy of pevonedistat plus capeOX in patients with advanced gastric cancer, presented at the 48th European Society for Medical Oncology Congress.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com